Fora Capital, LLC Arvinas, Inc. Transaction History

Fora Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	SELL	$36.38 - $52.31 $84,874 - $122,039	-2,333 Reduced 10.99%	18,895 $779,000
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $301,225 - $898,581	21,228 New	21,228 $873,000
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $79,129 - $116,607	-1,081 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$60.45 - $84.26 $103,732 - $144,590	-1,716 Reduced 61.35%	1,081 $83 Million
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $162,757 - $255,561	2,797 New	2,797 $185 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.